PTC Gets $1bn From Novartis For Phase II Huntington’s Candidate

Novartis will also pay up to $1.9bn for milestones and share US profits on the Phase II RNA-splicing candidate. PTC is discussing potential accelerated approval with the US FDA.

Novartis NIBR Cambridge, MA
Novartis adds another Huntington's disease candidate

More from Deals

More from Therapy Areas